Request Sample5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2018
SKU ID : GMD-11716329 | Publishing Date : 30-Jan-2018 | No. of pages : 39
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2018
Summary
According to the recently published report '5' Nucleotidase - Pipeline Review, H1 2018'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
The report '5' Nucleotidase - Pipeline Review, H1 2018' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Carcinoma, Peritoneal Cancer and Solid Tumor.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism o
Summary
According to the recently published report '5' Nucleotidase - Pipeline Review, H1 2018'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
The report '5' Nucleotidase - Pipeline Review, H1 2018' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Carcinoma, Peritoneal Cancer and Solid Tumor.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism o
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
24/7 Research Support
Phone: +1 424 253 0807 
